NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 318 filers reported holding NOVOCURE LTD in Q2 2022. The put-call ratio across all filers is 1.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $125 | -98.0% | 3 | -97.1% | 0.00% | – |
| Q1 2023 | $6,315 | -57.0% | 105 | -47.5% | 0.00% | – |
| Q4 2022 | $14,670 | -2.2% | 200 | 0.0% | 0.00% | – |
| Q3 2022 | $15,000 | +275.0% | 200 | +227.9% | 0.00% | – |
| Q2 2022 | $4,000 | – | 61 | +6000.0% | 0.00% | – |
| Q1 2022 | $0 | -100.0% | 1 | -95.0% | 0.00% | – |
| Q4 2021 | $2,000 | 0.0% | 20 | +42.9% | 0.00% | – |
| Q3 2021 | $2,000 | -93.8% | 14 | -90.3% | 0.00% | – |
| Q2 2021 | $32,000 | +3100.0% | 145 | +866.7% | 0.00% | – |
| Q1 2020 | $1,000 | – | 15 | +400.0% | 0.00% | – |
| Q4 2019 | $0 | -100.0% | 3 | -98.8% | 0.00% | – |
| Q1 2016 | $4,000 | – | 250 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |